Research output per year
Research output per year
Personal profile
Headline
ASSISTANT PROFESSOR | Hematology and Oncology
Fingerprint
Dive into the research topics where Deborah Doroshow is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Ma, J., Liu, W., Li, J., Kim, D., Kim, S., Levy, A., Cai, Z., Bunker, K. D., Recio-Boiles, A., Segar, J. M., Sen, S., Doroshow, D. B., Jandial, D., Rutgard, M., Harismendy, O., Grant, S. K., Samatar, A. A., Fischer, K. M. & Lackner, M. R., 1 Aug 2025, In: Molecular Cancer Therapeutics. 24, 8, p. 1171-1185 15 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Clinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population
Argulian, A., Hyfte, G. V., Baldwin, E., Kulshrestha, A., Lucas, N., Wilk, J., Wu, K., Yuan, M., Fazilov, G., Fitzgerald, L., Hapanowicz, O., Osorio, M., Cuevas, J., Wawrzyniak, A., Acuna-Villaorduna, A., Zamarin, D., Feng, D., Galsky, M. D., Marron, T. U. & Doroshow, D. B., 2025, In: Journal of Clinical Oncology. 43, 16, e13514.Research output: Contribution to journal › Article › peer-review
-
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers
Kim, D., Chung, H., Liu, W., Jeong, K., Ozmen, T. Y., Ozmen, F., Rames, M. J., Kim, S., Guo, X., Jameson, N., de Jong, P. R., Yea, S., Harford, L., Li, J., Mathews, C. A., Doroshow, D. B., Charles, V. J., Kim, D., Fischer, K. & Samatar, A. A. & 9 others, , Dec 2025, In: npj Precision Oncology. 9, 1, 3.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
Documentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials
Karol, A. B., Paredes, R., Argulian, A., Joshi, H., Weintraub, L., Oguntuyo, K., Miller, J., Fujiwara, Y., Doroshow, D. B. & Galsky, M. D., 1 Oct 2025, In: Cancer. 131, 19, e70106.Research output: Contribution to journal › Article › peer-review
-
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials
Blanter, J., Van Hyfte, G., Ahmad, M., Xu, S., Hapanowicz, O., Fazilov, G., Lu, A., Lucas, N., Wu, K., Shelton, G., Demerchant, M., Lachowicz, M., Kier, M., Werner, M., Eder, J. P., Galsky, M. D., Marron, T. U., Smith, C. B., Lorusso, P. M. & Hofstatter, E. & 1 others, , 1 Jun 2025, In: JCO Oncology Practice. 21, 6, p. 862-875 14 p.Research output: Contribution to journal › Article › peer-review
Press/Media
-
Studies from Icahn School of Medicine at Mount Sinai Have Provided New Information about Solid Cancer (Financial Toxicity Among Patients With Advanced Solid Tumors Participating In Early-phase Clinical Trials)
Doroshow, D., Galsky, M., Smith, B., Marron, T. & Smith, B.
1/07/25
1 item of Media coverage
Press/Media
-
Experts Sound the Alarm on Rare Cancer That's Quadrupled in Young People
11/06/25
1 item of Media coverage
Press/Media
-
Appendix cancers on the rise in younger generations, study finds
9/06/25 → 11/06/25
12 items of Media coverage
Press/Media
-
Appendix cancer rates skyrocketing among Gen X and millennials, new study finds
10/06/25
2 items of Media coverage
Press/Media
-
Study: Appendix cancer rising fast among Millennials and Gen X adults | The Jerusalem Post
Chan, A. & Doroshow, D.
10/06/25
1 item of Media coverage
Press/Media